CJC-1295 No DAC 10mg
Full-Protocol CJC-1295 No DAC for Comprehensive GH Research
The 10mg CJC-1295 No DAC vial provides the optimal research quantity for complete GH secretion and pituitary function protocols at the best value.
Full-Protocol CJC-1295 No DAC for Comprehensive GH Research
Double the 5mg entry size for comprehensive GH pulse research, combination protocol studies with Ipamorelin, and multi-week GH axis investigation.
As one of the most studied compounds in the growth & body comp research space, CJC-1295 has attracted sustained scientific interest across Extended GH axis research, Complete pituitary function protocols. Peer-reviewed evidence indicates that optimal quantity for full GH protocols, which has positioned CJC-1295 as a reference standard for researchers exploring extended gh axis research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
CJC-1295 Documented Benefits: 1 Documented Mechanisms
Extended Protocol Supply
Sufficient for multi-week CJC/Ipa combination protocols and comprehensive GH research.
How CJC-1295 Works: Molecular Mechanism & Pathway
Same modified GHRH(1-29) receptor activation mechanism as the 5mg variant.
The 1 primary research pathways identified for CJC-1295 — Extended Protocol Supply — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that popular for CJC/Ipa combination research, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, CJC-1295's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
CJC-1295 is routinely studied alongside Ipamorelin and CJC-1295 in growth & body comp-focused compound panels. Researchers investigating extended gh axis research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 99.2% purity has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All CJC-1295 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Optimal quantity for full GH protocols
- Popular for CJC/Ipa combination research
- 99.2% purity
Ideal For
- Extended GH axis research
- Complete pituitary function protocols
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on CJC-1295. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Optimal quantity for full GH protocols
Popular for CJC/Ipa combination research
99.2% purity
Third-Party Verified Every Batch
Each vial of CJC-1295 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
